Noxopharm Ltd has released a press release.
March 2023 Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
- Noxopharm Announces Novel mRNA Vaccine Enhancer
- Appendix 4D and Half Year 2023 Financial Report
- December 2022 Quarterly Activities Report and Appendix 4C
- DARRT-2 Trial Efficacy Phase to Commence
Later from Noxopharm
- Study results show new Sofra drug reduces inflammation
- IONIC Trial Abstract Published at ASCO
- June 2023 Activities Report and Appendix 4C
- Appendix 4E and Audited Financial Statements
- Latest CRO-67 data shows success in reducing cancer growth
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm